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Background: Tumor length is an important prognostic factor for many carcinomas, but its role in esophageal
cancer remained undetermined. The aim of this study was to investigate the effect of tumor length on survival for
patients with confined tumors (grade pT1-2) without lymph-node metastases in esophageal squamous cell
carcinoma.
Methods: We enrolled 201 patients with esophageal squamous cell carcinoma (SCC) who had undergone surgical
resection and been confirmed as pT1-2N0M0. The relationship of tumor length with overall survival was assessed
and compared with other factors detailed in the American Joint Committee on Cancer (AJCC) tumor, node,
metastasis (TNM) staging system published in 2009.
Results: The overall survival (OS) rates at 1, 3, and 5 years were 93.0%, 83.7%, and 69.2%, respectively. The tumor
length adversely affected OS, with the 5-year rate being 93.5%, 82.0%, 68.6%, 67.9%, 55.3% and 41.1%, respectively
for tumor lengths of less than 10 mm, 10 to 20 mm, 20 to 30 mm, 30 to 40 mm, 40 to 50 mm, and greater than
50 mm (P< 0.001). Multivariate analyses showed that the pathologic T classification and grade of tumor was
significantly associated with OS. Tumor length of 30 mm or more remained an independent prognostic factor
(P = 0.04), as did the other current TNM factors.
Conclusion: Tumor length appears to affect the OS of patients with early-stage esophageal squamous cell
carcinoma. It may provide additional prognostic information for the current TNM staging system.
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Before 1987, the American Joint Committee on Cancer
(AJCC) staging system used tumor length to predict pa-
tient prognosis [1]; however, the current TNM staging
system, first published in 2009, did not take tumor
length into account [2]. In the current AJCC staging sys-
tem for esophageal tumors, stage depends on the depth
of the tumor (T classification), lymph-node (LN) in-
volvement (N classification), and distant metastasis (M
classification).* Correspondence: yipingzhang@yahoo.cn
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reproduction in any medium, provided the orRecent publications have suggested that pathologic
esophageal tumor length is directly correlated with long-
term survival [3-6]; however, most of these data origi-
nated in western countries, and the cancer type was
predominantly adenocarcinoma.
The aim of this study is to evaluate the value of tumor
length and other prognostic factors in predicting the be-
havior of early-stage esophageal squamous cell carcin-
oma (SCC) without LN involvement, and the outcome
after definitive surgery for such cases, in a Chinese
population.Methods
We assessed patients who had undergone surgical resec-
tion for esophageal cancer between January 2002 and
December 2008 in Zhejiang Cancer Hospital. The totaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic characteristics of the study
population
Variable




Range 31 to 78
Median 59
< 65, n (%) 156 (77.6)
≥ 65, n (%) 45 (22.4)




Well or moderately differentiated 158 (78.6)
Poorly differentiated or undifferentiated 43 (21.4)
Tumor length
Mean ± SD 4.0 ± 2.5
≤ 30 mm, n (%) 115 (57.2)
> 30 mm, n (%) 86 (42.8)




Tumor location, n (%)
Upper third 12 (5.9)
Middle third 102 (50.7)
Lower third 87 (43.4)
No. of examined LNs, n (%)
< 18 29 (14.4)
≥ 18 172 (85.6)
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a pathological diagnosis of T1-2; 199 of these had LN
metastasis, and were excluded. Of the 232 patients with-
out LN metastasis, 13 did not have microscopically
tumor-free margin (R0), and a further 18 either had
fewer than 12 dissected LNs or had a cancer type other
than SCC, and these were also excluded, leaving 201
patients for analysis.
All of the 201 patients with complete tumor resection
had pathologically confirmed SCC. The tumor length
was measured immediately after resection. Preoperative
evaluation and staging investigations included a
complete medical history and physical examination,
complete blood count and serum biochemistry tests, and
scans (for example, computed tomography (CT) of the
thorax, ultrasonography of the upper abdomen, magnetic
resonance imaging of the brain, total body bone scan,
and fluorodeoxyglucosepositron emission tomography).
Treatment
The extent of the esophageal resection and LN dissec-
tion were decided at the time of the operation by the
surgeons and took into account the general physical
condition of the patient. None of the patients received
adjuvant chemotherapy after surgery.
Follow-up
The surviving patients were followed up every 3 to
6 months for the first 5 years, then annually. Recording
of medical history, physical examination, and CT of the
chest were performed during the follow-up time. Endo-
scopic examination and whole-body examination were
obtained in cases of clinically indicated recurrence or
metastasis. Survival was measured from the date of
surgery to the date of death or the final follow-up visit,
with. June 2011 being the final censoring date for
survival. The median time from surgery to the final cen-
soring date was 52 months (range 30 to 136 months).
Statistical analysis
The Kaplan–Meier method was used to estimate survival
curves. The definition of survival was determined from
the date of surgery and the final known follow-up or the
date of death. A univariate Cox proportional hazards re-
gression model was used to examine the association be-
tween various prognostic predictors and survival.
Possible prognostic factors associated with survival
probability at a significance level of less than or equal to
0.20 were considered in a multivariable Cox propor-
tional hazards regression analysis. P< 0.05 was regarded
as significant. All statistical tests were analyzed using
SPSS software) version 16.0; SPSS Inc, Chicago, IL,
USA).Results
Patient characteristics
Table 1 shows the clinical characteristics of the 201
included patients. The population was predominantly
male (86.6%), with a median age of 59 years (range 31–
78 years). The most common tumor location was the
middle and lower esophagus (94.1%). Of the 201
patients, 115 patients had a tumor length of 30 mm or
less and 86 patients had a tumor length greater than 30
mm. The mean and median lengths of the esophageal
tumors were 40 and 28 mm, respectively. There were
168 patients who had undergone Ivor-Lewis esophageal
resection, and these were categorized as one group for
analysis, while patients who had undergone a tri-
incisional esophageal resection (n = 25) or any other ap-
proach (n = 8) were categorized together as another
group. The mean number of LNs dissected was 24.9
(range 13 to 72).
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Survival time was assessed against increasing length of
the tumor in 10-mm increments. As previous reports
reported that 30 mm was a well separation [3-6], we
used this length to evaluate survival time.
There was a significant difference in survival between
patients with tumors of 30 mm or less and patients with
tumors greater than 30 mm (P = 0.01) (Figure 1). When
survival was analyzed using size as a continuous variable,
there was also a statistical association, with the 5-year
survival rate being 93.5%, 82.0%, 68.6%, 67.9%, 55.3%,
and 41.1% for tumor lengths of less than 10 mm, 10 to
20 mm, 20 to30 mm, 30 to 4 mm, 40 to 50 mm, and
more than 50 mm, respectively (P< 0.001) (Figure 2).
When survival was analyzed by tumor stage (T1 and
T2), the length was also a significant prognostic factor
(P = 0.04 and P = 0.02, respectively: Figure 3, Figure 4).
There was a significant difference in 5-year survival in
T1a patients when sub-grouped as having tumors of
30 mm or less and tumors greater than 30 mm (91.0%
versus 82.5%, P< 0.05;),and similar in T1b when sub-
grouped as having tumors of 30 mm or less and tumors
greater than 30 mm(81.5% versus 72.2%, P< 0.04). Simi-
larly, the 5-year survival difference in T2a and T2b
patients was also found when they were sub-grouped by
tumor size with the cut-off of 30 mm (78.5% versus
71.1%, P = 0.04; 65.2% versus 57.2%, P = 0.01).Figure 1 Kaplan–Meier survival curves in 201 patients with R0-resecte
less and greater than 30 mm (P = 0.01).Factors affecting overall survival assessed by univariate
and multivariate analysis
Univariate analyses were performed using the Kaplan-
Meier method to assess the predictive capability of each
variable assessed (Table 2). As expected, pathologic T
classification, tumor grade, and tumor length were pre-
dictive of survival. Age, gender, tumor location, surgical
procedure, and number of examined LNs were not sig-
nificantly associated with OS.
Variables used in the final model included age, gender,
tumor location, pathologic T stage, surgical procedure,
number of examined LNs and tumor length (Table 3). A
multivariate Cox regression model was constructed to
incorporate age, gender, histologic grade, and the tumor
depth, location, and length (30 mm or less versus more
than 30 mm). Tumor length (30 mm or less versus more
than 30 mm), tumor depth, and histologic grade
remained as independent prognostic factors (Table 3),
but age, gender, and tumor location did not have a sig-
nificant influence on survival in multivariate analysis.Discussion
To our knowledge, this is one of the largest studies to
evaluate the value of tumor length in predicting patient
prognosis for resectable early-stage esophageal SCC. We
found that pathologic esophageal tumor length wasd esophageal carcinoma, comparing tumor length of 30 mm or
Figure 2 Kaplan–Meier survival curves in 201 patients with R0-resected early-stage esophageal carcinoma comparing tumor length in
10 mm increments (P<0.001).
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Our results suggest that tumor length might be a valu-
able prognostic factor and might help to identify a high-
risk group of patients after surgery for early-stage
esophageal SCC.Figure 3 Kaplan–Meier survival curves in 91 patients assessed as pT1
30 mm (P = 0.04).According to the guidelines of the National Compre-
hensive Cancer Network, systemic chemotherapy is not
recommended for esophageal carcinoma of pT1-2 with-
out LN metastases; observation after complete tumor
resection is the recommended approach. However, the, comparing tumor length of 30 mm or less and greater than
Figure 4 Kaplan–Meier survival curves in 110 patients assessed as pT2, comparing tumor length of 30 mm or less and greater than
30 mm (P = 0.017).
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useful to assess possible risk factors in addition to tumor
depth and grade. In other cancers, such as lung and
breast cancers, tumor size is an important prognostic
factor for predicting long-term survival, where as only
tumor depth and grade are considered prognostic factors
in the p-TNM staging for esophageal carcinoma [7].
Eloubeidi et al. [4] proposed a revised TNM classifica-
tion for esophageal carcinoma to include tumor length.
Other authors have also indicated the importance of
tumor length for prognosis; however, most of these data
were based on western populations, with the tumor type
being predominantly adenocarcinoma [8-10].
In our study, we attempted to eliminate any influence
of LN metastases by focusing only on the pathologic
esophageal tumor length. In addition, we selected only
patients who had undergone esophagectomy with
complete tumor R0 resection achieved; any cases with-
outR0 resection was excluded. Our study clearly demon-
strates that tumor length is an independent predictor of
long-term survival, and association of tumor length with
survival was consistent regardless of whether length was
analyzed as a continuous or categoric variable (Figure 1,
Figure 2). In addition, this effect was present even when
the other standard staging prognostic factors (pTNM)
were taken into account.
The question of how many LNs should be dissected
has been a point of debate in previous studies [11-13].
Greenstein et al. [14]. and Yang et al. [15] recommended
18 as the minimum number of resectable LNs, whereas
Peyre et al. [16] recommended a minimum of 23regional LNs, and Schwarz and Smith recommended at
least 30 LNs be removed for an adequate lymphadenect-
omy [17]. However, most previous studies were included
patients with locally advanced cancers. The LN dissec-
tion number was not clear in early-stage esophageal car-
cinoma. We did not find any survival difference when
using 18 LNs as a cut-off point in our data.
As noted by other authors, Tumor depth also corre-
lated with long-term outcome in patients with different
pT disease stages, as reported previously by other
authors [9,11]. The overall 5-year survival rates for pT1
and T2 were 76.2% and 67.4%, respectively in this study.
Similarly, level of differentiation (well/moderately versus
poorly/not) was also a strong prognosis factor in our
study (P = 0.04).
Our study has several limitations. It was a retrospect-
ive study with all the limitations that accompany such a
study. In addition, because the study used data from a
single institution but with different pathologists and dif-
ferent surgeons, there may have been a lack of uniform-
ity in measurement methods. The LN dissection number
was also not consistent, and we also excluded patients
who had a dissected LN number of less than 12, which
may have influenced our analysis. Thus, carefully designed
prospective studies are needed to confirm the role of
tumor length in guiding esophageal SCC treatment.
Conclusion
In summary, our study suggests that esophageal tumor
length in early-stage esophageal SCC without LN in-
volvement could be a useful prognostic factor to help
Table 2 Results of univariate analysis of the prognosis of
201 patients with esophageal carcinoma
Variable Number Survival,% P value
3 years 5 years
Gender 0.23
Male 174 82.4 70.2
Female 27 92.6 77.8
Age, years 0.94
≥ 65 45 77.2 74.2
< 65 156 85 67.6
Surgical procedure 0.74
Ivor-Lewis 168 83.6 73.5
Tri-incisional 25 83.8 65.5
Other 8 87.5 46.7
Tumor grade 0.05
T1 91 88.8 76.2
T2 110 79.8 67.4
Tumor length, mm 0.01
> 30 86 89.5 78.9
≤ 30 115 76.4 61.6
Histologic grade
Well or moderately differentiated 158 86.3 74.3 0.04
Poorly differentiated 43 74.4 60.9
Tumor location 0.68
Upper third 12 83.3 55.6
Middle third 102 86 74.3
Lower third 87 81.4 70.1
Lymph-node size, mm 0.33
≥ 180 172 84.6 72.9
< 180 29 79.2 62.3
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surgical resection. We found that esophageal tumor
length was a significant independent predictor of long-
term survival. We consider that it should be incorpo-
rated in the current esophageal cancer staging system toTable 3 Terms included in the final multivariate model






Gender 0.510 0.182 to 1.433 0.20
Age 0.774 0.389 to 1.540 0.47
Surgical approach 1.076 0.494 to 2.344 0.85
Tumor classification 1.698 1.192 to 2.985 0.04
Tumor length 2.161 1.178 to 3.965 0.04
Histologic grade 2.016 1.081 to 3.763 0.03
Tumor location 0.893 0.543 to 1.468 0.65
Number of examined LNs 0.514 0.228 to 1.159 0.11
LN, lymph node.better predict the long-term survival of patients with
esophageal cancer.
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